Zealand Pharma A/S is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. Founded in 1998 and headquartered in Søborg, Denmark, it foc... Zealand Pharma A/S is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. Founded in 1998 and headquartered in Søborg, Denmark, it focuses on addressing unmet medical needs in obesity, rare diseases, and chronic inflammation through its validated peptide platform. This expertise has produced over 10 drug candidates advancing to clinical development, with two reaching the market via partnerships. Key products include Zegalogue, a single-use syringe or autoinjector for severe hypoglycemia treatment, and dasiglucagon for congenital hyperinsulinism and bi-hormone artificial pancreas systems. The pipeline features obesity assets like petrelintide (long-acting amylin analog), dapiglutide (GLP-1/GLP-2 dual agonist), and survodutide in Phase 3; rare disease candidates for short bowel syndrome; and inflammation programs such as ZP9830 (Kv1.3 blocker). With around 355 employees, predominantly in R&D, Zealand pursues global partnerships to commercialize therapies, leveraging 25+ years of peptide innovation to enhance biological activity and stability for better patient outcomes.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

No Climate Targets data disclosed by Zealand Pharma

We reviewed Zealand Pharma's website and available disclosure materials for the 2023 reporting period and did not identify any reported Climate Targets data.

If you would like us to review newly published materials or reassess the most recent disclosures, you can submit a data update request.

Would you like us to review Zealand Pharma's data?

Start your 30-day free trial to request a data review for Zealand Pharma.

Start Free Trial

Legal Center Contact Us